FDA official quits over Plan B decision

Share this article:
The FDA's Office of Women's Health (OWH) director has resigned in protest over the agency's refusal to permit OTC sales of Barr's Plan B emergency contraceptive.
OWH director Susan Wood announced her resignation in an e-mail to agency colleagues.
The FDA declined to comment on Wood's departure.
The agency announced it would defer a decision on the politically sensitive drug, pending a 60-day public comment period. That decision came despite an earlier promise to Congress from FDA Commissioner Lester Crawford to make a final decision on Plan B by Sept. 1.
Senators Hillary Clinton (D-N.Y.) and Patty Murray (D-Wash.) placed a hold on Crawford's nomination to commissioner in June, demanding a yes or no decision on the drug, but relented in July when he issued a Sept. 1 deadline.
"It is deeply disturbing that an agency long recognized for making decisions based on sound science has become so politicized that one of its most widely respected, long-serving veterans would feel disillusioned enough to quit in protest," Clinton and Murray said in a joint statement.
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.